The nomination of new directors by a significant shareholder often leads to increased investor scrutiny and potential strategic changes. Given Shah Capital's critique of Novavax's management and strategy, this move could be seen positively by the market, anticipating that the proposed changes might address the company's underperformance and capitalize on untapped opportunities.